Pfizer Inc. $PFE Shares Sold by Venture Visionary Partners LLC

Posted by Francis Steltz on Jun 16th, 2026

Venture Visionary Partners LLC lowered its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 13.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 158,890 shares of the biopharmaceutical company’s stock after selling 24,774 shares during the quarter. Venture Visionary Partners LLC’s holdings in Pfizer were worth $4,028,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PFE. Horizon Financial Services LLC raised its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. YANKCOM Partnership acquired a new stake in Pfizer in the 4th quarter valued at about $28,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s CEO said the company could eventually return to high-single-digit growth, suggesting the business may be stronger than investors expect and improving the long-term growth narrative. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
Positive Sentiment: Pfizer’s obesity pipeline got a boost after Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and support for moving into Phase 3, which could add a new growth driver. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
Positive Sentiment: RBC Capital upgraded Pfizer, reinforcing the view that the stock’s dividend and valuation may be attractive relative to peers. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
Neutral Sentiment: Pfizer is drawing heavy investor search interest and additional research coverage, indicating rising attention but not necessarily a direct fundamental catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Neutral Sentiment: Analyst commentary continues to focus on Pfizer’s discounted valuation, fading COVID revenues, and looming patent expirations, leaving the stock’s longer-term rerating story still uncertain. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?
Neutral Sentiment: Pfizer was also included in a “Top Research Reports” roundup, which adds visibility but does not appear to change the investment thesis on its own. Top Research Reports for Pfizer, Altria & Newmont Corp.
Negative Sentiment: Ongoing concerns about patent cliffs and declining legacy COVID-related sales continue to cap enthusiasm for Pfizer’s near-term earnings growth. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Analyst Ratings Changes

A number of research firms have issued reports on PFE. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.82.

Get Our Latest Stock Report on Pfizer

Pfizer Trading Down 0.8%

PFE opened at $26.01 on Tuesday. The firm has a market cap of $148.24 billion, a price-to-earnings ratio of 19.86 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The business’s 50 day moving average is $26.38 and its two-hundred day moving average is $26.33. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.